Sensorion Announces the Appointment of Laurene Danon as Chief Financial Officer
June 27 2024 - 12:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the
development of novel therapies to restore, treat and prevent within
the field of hearing loss disorders, today announces the
appointment of Ms Laurene Danon as Chief Financial Officer.
Laurene brings to Sensorion more than 15 years of experience in
investment banking and international equity capital markets. A
graduate of HEC, she began her career in London with the investment
bank J.P. Morgan, in corporate finance advisory, before
specializing in equity capital markets at J.P. Morgan and later at
Jefferies International. Prior to joining Sensorion, she founded
the strategic advisory firm Concorde Advisory, where she supported
and managed the execution of strategic corporate finance projects
for her clients. In total, Laurene has led executions for 70
transactions totaling over $35 billion raised.
Laurene was well known to the Sensorion team, having advised the
company on recent capital increases.
Laurene Danon, Chief Financial Officer of Sensorion,
said: "I am delighted to have the opportunity to join Sensorion
at a pivotal moment in its history, marked by a strong acceleration
of its programs, particularly in gene therapy. These programs are
currently receiving strong support from the medical community,
patients and their families, as well as investors. I am determined
to work with the whole team at Sensorion to further develop highly
innovative therapies for hearing disorders, a significant global
unmet medical need."
Nawal Ouzren, Chief Executive Officer of Sensorion, said:
“I am excited to welcome Laurene whose appointment represents
excellent news for Sensorion and comes at a time of significant
opportunity and growth for Sensorion. She brings a wealth of
knowledge that will play a paramount role in supporting advances in
Sensorion’s pipeline. With her proven expertise of international
capital markets, she will be a great addition to our management’s
team and will immensely contribute in Sensorion’s mission to bring
potentially life-transformative solutions to people living with
hearing disorders.”
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which
specializes in the development of novel therapies to restore,
treat, and prevent hearing loss disorders, a significant global
unmet medical need. Sensorion has built a unique R&D technology
platform to expand its understanding of the pathophysiology and
etiology of inner ear related diseases, enabling it to select the
best targets and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary
monogenic forms of deafness, developed in the framework of its
broad strategic collaboration focused on the genetics of hearing
with the Institut Pasteur. SENS-501 (OTOF-GT) currently being
developed in a Phase 1/2 clinical trial, targets deafness caused by
mutations of the gene encoding for otoferlin and GJB2-GT targets
hearing loss related to mutations in GJB2 gene to potentially
address important hearing loss segments in adults and children. The
Company is also working on the identification of biomarkers to
improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small
molecule programs for the treatment and prevention of hearing loss
disorders. Sensorion’s clinical-stage portfolio includes one Phase
2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2
proof of concept clinical study of SENS-401 in Cisplatin-Induced
Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of
SENS-401 in patients scheduled for cochlear implantation. A Phase 2
study of SENS-401 was also completed in Sudden Sensorineural
Hearing Loss (SSNHL) in January 2022.
www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer
This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be
reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
2023 full year report published on March 14, 2024, and available on
our website and to the development of economic conditions,
financial markets and the markets in which Sensorion operates. The
forward-looking statements contained in this press release are also
subject to risks not yet known to Sensorion or not currently
considered material by Sensorion. The occurrence of all or part of
such risks could cause actual results, financial conditions,
performance or achievements of Sensorion to be materially different
from such forward-looking statements. This press release and the
information that it contains do not constitute an offer to sell or
subscribe for, or a solicitation of an offer to purchase or
subscribe for, Sensorion shares in any country. The communication
of this press release in certain countries may constitute a
violation of local laws and regulations. Any recipient of this
press release must inform oneself of any such local restrictions
and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240626797971/en/
Investor Relations Noémie Djokovic, Investor Relations
and Communication Associate ir.contact@sensorion-pharma.com
Press Relations Ulysse Communication Bruno Arabian / 00
00(0)6 87 88 47 26 barabian@ulysse-communication.com Nicolas Entz /
00 33 (0)6 33 67 31 54 nentz@ulysse-communication.com
Sensorion (EU:ALSEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sensorion (EU:ALSEN)
Historical Stock Chart
From Jul 2023 to Jul 2024